Triple T Psychiatry

Directions Website Contact the business

Triple T Psychiatry Our model of care is based on a holistic approach to primary care, behavioral health, and a focused treatment plan for optimal wellness.

At PMG, we offer integrated functional medicine. Our model of care is based on a holistic approach to primary care, behavioral health, an in-depth analysis, and a focused treatment plan for optimal wellness.We also currently offer COVID-19 rapid tests, PCR tests, and vaccinations.

10/19/2026

STAMFORD, CONNECTICUT — A local doctor and his medical practices have agreed to pay $866,539 to settle government allegations involving COVID-19 relief payments and Medicare and Medicaid billing.

Federal and state authorities announced the settlement on October 16. Officials alleged that Dr. Steven Murphy and his practices sought reimbursement for treating uninsured COVID-19 patients even though records indicated some patients had health insurance. Authorities also alleged that Medicare and Medicaid were billed for certain blood tests that were never performed.

— As part of the agreement, Murphy and his practices will be excluded from federal healthcare programs for three years.

The settlement resolves civil allegations under the False Claims Act. It is not a criminal conviction, and the allegations should not be treated as a criminal finding of guilt.

10/19/2026

RHODE ISLAND, USA — CVS has agreed to pay $315 million to settle a federal lawsuit alleging it unlawfully filled opioid prescriptions and billed government healthcare programs for many of them.

Announced on October 13, the settlement addresses allegations that CVS filled prescriptions that lacked a legitimate medical purpose, including prescriptions for excessive quantities of opioids and those linked to suspected “pill mill” prescribers.

— The agreement also requires CVS to strengthen its monitoring of prescription patterns and create a reporting hotline for suspected illegal dispensing.

CVS disputes the government’s allegations and did not admit wrongdoing. The settlement resolves civil claims without a determination of liability.

10/18/2026

CAPE COD, MASSACHUSETTS — A Cape Cod man has pleaded guilty to conspiring to launder proceeds from a $6 million Medicare fraud scheme, according to federal authorities.

The guilty plea was announced on October 13. Investigators are examining the financial trail connected to the healthcare fraud case, focusing on how money allegedly obtained through the scheme was handled.

— Financial investigations like this can extend beyond the original fraudulent claims, as authorities work to trace where the proceeds went and who was involved.

The case highlights how healthcare fraud investigations can expand into financial networks beyond the clinics or suppliers submitting claims.

10/18/2026

NEW HAMPSHIRE, USA - A former New Hampshire doctor has been sentenced to one year in federal prison for his role in a Medicare fraud scheme involving approximately $1.9 million.

Federal authorities announced the sentence on October 13, bringing renewed attention to fraudulent medical billing and the misuse of taxpayer-funded healthcare programs.

— The case raises important questions about healthcare oversight, fraudulent Medicare claims, and accountability when licensed medical professionals are involved in improper billing schemes.

For older Americans who rely on Medicare, protecting public healthcare funds helps ensure resources remain available for legitimate medical care.

10/17/2026

JOHNSON COUNTY, KANSAS — A Kansas businessman has been sentenced to 19 years in federal prison for his role in a Medicare fraud operation involving more than $1 billion in fraudulent claims.

Brett Blackman, 43, operated a healthcare software platform that prosecutors said helped generate fake doctors’ orders for medically unnecessary braces and other medical equipment. The scheme allegedly targeted hundreds of thousands of Medicare beneficiaries across the United States.

— Investigators say the operation used technology to turn false medical paperwork into a massive fraud scheme targeting a taxpayer-funded healthcare program.

The case highlights how healthcare technology can be abused to generate fraudulent claims on a national scale.

10/17/2026

Could artificial intelligence help drugmakers avoid costly clinical-trial failures? A new report highlights how pharmaceutical companies in the United States and around the world are testing AI-powered virtual patients to predict whether experimental medicines might work before launching major human studies.

In a Reuters report published October 7, AI company BioinvestGPT reportedly predicted that Novartis’ experimental muscular-dystrophy drug, del-desiran, would deliver limited clinical benefits. Its later-stage trial subsequently failed to meet its primary goal.

— Companies hope these simulations can identify weaker drug candidates earlier, potentially saving time and money while helping researchers focus resources on more promising treatments.

But virtual trials have limits, and AI predictions can be wrong. Real human clinical trials remain essential to determine whether medicines are safe and effective for patients.

10/16/2026

A major lung-disease research update for patients across the United States: Bristol Myers Squibb says its experimental drug admilparant met the main goal in a Phase 3 trial for idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring.

Announced on October 12, the results showed that the 60 mg dose significantly improved the change in forced vital capacity (FVC)—a measure of how much air a person can exhale—compared with placebo after 52 weeks. The higher, 120 mg dose did not reach statistical significance.

— The findings could move researchers closer to another potential treatment for people living with IPF, which can gradually reduce lung function and make everyday activities more difficult.

Admilparant remains investigational and is not yet approved. Bristol Myers Squibb says detailed results will be presented at a future medical meeting, so the size of the benefit still needs closer review.

10/16/2026

A new development in cancer research could matter for patients across the United States and Canada living with rare, advanced neuroendocrine tumors of the digestive system.

On October 12, Bristol Myers Squibb announced positive Phase 3 results for RYZ101, an experimental targeted radiopharmaceutical treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The ACTION-1 trial met its primary goal, showing a statistically significant improvement in the time patients lived without their cancer progressing compared with standard treatment options.

— The findings are especially relevant to patients whose tumors progressed after earlier lutetium-177-based treatment and who may have limited options remaining.

RYZ101 is not yet FDA-approved. The company has not released detailed trial results, and further regulatory discussions are planned. The findings are encouraging, but more information is needed to understand the size of the benefit and its impact on overall survival.

10/15/2026

A new treatment option is now available for certain immunocompromised adults in the United States dealing with persistent herpes simplex virus (HSV) lesions that have not responded to standard antiviral medicines.

On October 9, the U.S. Food and Drug Administration approved Hovilpri (pritelivir) for eligible adults whose HSV lesions have not responded to medicines such as acyclovir, valacyclovir, or famciclovir.

In the Phase 3 clinical trial, all lesions had healed by day 28 in 63% of patients receiving Hovilpri, compared with 34% receiving other selected treatments. The approval gives patients with weakened immune systems another option for a difficult-to-treat infection.

Hovilpri does not cure HSV and is not intended for everyone with herpes. Its approval applies to a specific group of immunocompromised adults with treatment-refractory lesions.

10/15/2026

United States: the FDA has approved a new treatment combination for certain people with stage III colon cancer.

On October 8, the U.S. Food and Drug Administration approved atezolizumab, also known as Tecentriq, alongside chemotherapy for eligible patients whose tumors have a specific DNA-repair deficiency. The clinical trial included 712 patients and found a significant improvement in disease-free survival compared with chemotherapy alone.

— This approval could give eligible American patients and their oncology teams another option after surgery to help reduce the risk of cancer returning.

It is not intended for every colon cancer patient. Eligibility depends on the tumor’s specific characteristics and the treatment plan determined with a qualified cancer specialist.

Address

7426 N La Cholla Boulevard
Cortaro, AZ
85741

Opening Hours

Monday 8am - 4pm
Tuesday 8am - 4pm
Wednesday 8am - 4pm
Thursday 8am - 4pm
Friday 8am - 4pm

Website

Alerts

Be the first to know and let us send you an email when Triple T Psychiatry posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Triple T Psychiatry:

Shortcuts

Share

Category